The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.

Author(s): Clark RA, Mukandavire C, Portnoy A, Weerasuriya CK, Deol A, Scarponi D, Iskauskas A, Bakker R, Quaife M, Malhotra S, Gebreselassie N, Zignol M, Hutubessy RCW, Giersing B, Jit M, Harris RC, Menzies NA, White RGJournal: Lancet Glob HealthPMID: 36925175 April 2023
Tuberculosis is a leading infectious cause of death worldwide. Novel vaccines will be required to reach global targets and reverse…

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.

Author(s): Portnoy A, Clark RA, Quaife M, Weerasuriya CK, Mukandavire C, Bakker R, Deol AK, Malhotra S, Gebreselassie N, Zignol M, Sim SY, Hutubessy RCW, Baena IG, Nishikiori N, Jit M, White RG, Menzies NAJournal: PLoS MedPMID: 36693081 January 2023
Tuberculosis (TB) is preventable and curable but eliminating it has proven challenging. Safe and effective TB vaccines that can rapidly…